Biogen Inc Cmn (BIIB) 314.81 $BIIB Stock Market News for

New Post Public Reply Private Reply Replies (0) Message Board

Sep 22, 2016 at 7:17 PM

Biogen Inc Cmn (BIIB) 314.81 $BIIB

Stock Market News for September 21, 2016
Zacks Equity Research - Zacks Investment Research - Wed Sep 21, 9:22AM CDT
Benchmarks finished slightly higher on Tuesday ahead of the two-day policy meetings of the Fed and Bank of Japan (BOJ) ending today
FDX: 173.66 (-0.20), AGN: 243.43 (+5.02), PBR: 9.56 (+0.05), BIIB: 314.81 (+2.81), SON: 53.50 (+0.46), GILD: 81.52 (-0.18), FB: 130.08 (+0.14), XOM: 83.54 (+0.24), AMGN: 175.62 (+1.77), KBH: 15.65 (+0.42), TBRA: 39.50 (+0.42)

Biotech Stock Roundup: Tobira Soars on Acquisition Deal, FDA Says Yes to Sarepta DMD Drug
Arpita Dutt - Zacks Investment Research - Wed Sep 21, 7:39AM CDT
The biotech sector got a boost with Allergan announcing its intention to acquire Tobira as well as a couple of other companies.
BIIB: 314.81 (+2.81), VRTX: 92.12 (+0.30), GERN: 2.22 (-0.03), SRPT: 60.97 (+4.75), TBRA: 39.50 (+0.42), ALKS: 51.00 (+0.52), REGN: 408.01 (+1.49)

Biogen Idec Has Returned 23.9% Since SmarTrend Recommendation (BIIB)
Comtex SmarTrend(R) - Tue Sep 20, 1:00PM CDT
SmarTrend identified an Uptrend for Biogen Idec (NASDAQ:BIIB) on July 7th, 2016 at $247.44. In approximately 3 months, Biogen Idec has returned 23.93% as of today's recent price of $306.65.
BIIB: 314.81 (+2.81)

Look for Shares of Biogen Idec to Potentially Pullback after Yesterday's 1.70% Rise
Comtex SmarTrend(R) - Tue Sep 20, 12:16PM CDT
Biogen Idec (NASDAQ:BIIB) traded in a range yesterday that spanned from a low of $304.00 to a high of $308.67. Yesterday, the shares gained 1.7%, which took the trading range above the 3-day high of $308.00 on volume of 552,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
BIIB: 314.81 (+2.81)

New Data Presented at ECTRIMS Reinforce Efficacy of ZINBRYTA(TM) (Daclizumab) and Support Long-Term Safety Profile
BusinessWire - Thu Sep 15, 6:30AM CDT
--Interim Analysis of EXTEND Study Shows Sustained ZINBRYTA Efficacy for Up to Five Years
BIIB: 314.81 (+2.81), ABBV: 65.08 (+0.98)

Biogen to Report Third Quarter 2016 Financial Results on October 26, 2016
BusinessWire - Wed Sep 14, 3:01PM CDT
Biogen Inc. (NASDAQ:BIIB) today announced it will report third quarter 2016 financial results on Wednesday, October 26, 2016, before the financial markets open.
BIIB: 314.81 (+2.81)

Biotech Stock Roundup: Horizon-Raptor Acquisition Deal, Geron Down on Pipeline News
Arpita Dutt - Zacks Investment Research - Wed Sep 14, 7:47AM CDT
With the Horizon-Raptor acquisition deal being announced, will the biotech sector see more such merger and acquisition announcements?
BIIB: 314.81 (+2.81), RPTP: 8.96 (-0.03), LXRX: 18.82 (-0.08), GILD: 81.52 (-0.18), GERN: 2.22 (-0.03), HZNP: 19.41 (+0.24), SPPI: 4.81 (+0.34)

New Data Affirm Strong Efficacy and Well-Characterized Safety Profile of TECFIDERA(R) in Both Clinical Studies and Real-World Setting
BusinessWire - Wed Sep 14, 6:30AM CDT
--a^' Benefit-Risk Profile of TECFIDERA Remains Favorable Up to Nine Years a^'
BIIB: 314.81 (+2.81)

Perrigo Up as Starboard Reveals Stake, Changes Proposed
Zacks Equity Research - Zacks Investment Research - Tue Sep 13, 3:30PM CDT
Perrigo's (PRGO) shares gained after the activist investor, Starboard, disclosed in a letter its 4.6% stake in the company, and prompted it to take immediate steps.
BIIB: 314.81 (+2.81), PRGO: 97.12 (+3.43), GERN: 2.22 (-0.03), MYL: 42.59 (+0.68)

Biotech Stocks Bounce Back in Monday Trading: 3 Picks
Zacks Equity Research - Zacks Investment Research - Tue Sep 13, 8:12AM CDT
Media and political focus on the high prices of drugs have made things difficult for the pharma/biotech sector since the past one year.
ABT: 42.22 (+0.30), BIIB: 314.81 (+2.81), VNDA: 16.62 (+1.06), PFE: 34.15 (-0.13), AMGN: 175.62 (+1.77), AEGR: 2.65 (+0.33), LLY: 81.29 (+0.42), PDLI: 3.35 (-0.01), JNJ: 119.46 (+0.55), GILD: 81.52 (-0.18), AZN: 34.28 (+0.53), MRK: 63.02 (+0.32), SNY: 38.57 (+0.19), NVS: 82.03 (+0.51)

Biogen Idec Shares Up 22.3% Since SmarTrend's Buy Recommendation (BIIB)
Comtex SmarTrend(R) - Tue Sep 13, 1:03AM CDT
SmarTrend identified an Uptrend for Biogen Idec (NASDAQ:BIIB) on July 7th, 2016 at $247.44. In approximately 2 months, Biogen Idec has returned 22.32% as of today's recent price of $302.66.
BIIB: 314.81 (+2.81)

Biogen Idec Set to Possibly Rebound After Yesterday's Selloff of 2.40%
Comtex SmarTrend(R) - Fri Sep 09, 12:59PM CDT
Biogen Idec (NASDAQ:BIIB) traded in a range yesterday that spanned from a low of $299.09 to a high of $305.48. Yesterday, the shares fell 2.4%, which took the trading range below the 3-day low of $307.42 on volume of 870,000 shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
BIIB: 314.81 (+2.81)

Biogen Idec Falls 2.40% on Heavy Volume: Watch For Potential Rebound
Comtex SmarTrend(R) - Fri Sep 09, 12:57PM CDT
Biogen Idec (NASDAQ:BIIB) traded in a range yesterday that spanned from a low of $299.09 to a high of $305.48. Yesterday, the shares fell 2.4%, which took the trading range below the 3-day low of $307.42 on volume of 870,000 shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
BIIB: 314.81 (+2.81)

Biogen Demonstrates Commitment to Improving Patient Outcomes with Study on Burden of MS and New Clinical Data from Its Leading MS Portfolio
BusinessWire - Thu Sep 08, 6:30AM CDT
--Comparative Effectiveness Studies Reinforce Clinical Data Supporting the Strong, Sustained Efficacy of TECFIDERA(R)
BIIB: 314.81 (+2.81), ACOR: 27.22 (+0.15)

These Stocks are Predicted to Outperform this Week According to Forcerank
ESTMZ - Wed Sep 07, 10:10AM CDT
Each week Forcerank runs a variety of games covering different industries. What we have found, is that the highest ranked companies in their respective games deliver the greatest positive price movement for that week. This week the winners include...
UA: 39.90 (+0.29), TSLA: 206.43 (+1.21), BIIB: 314.81 (+2.81), AMZN: 804.70 (+14.96), SPY: 217.18 (+1.36), FB: 130.08 (+0.14), XOM: 83.54 (+0.24), AAPL: 114.62 (+1.07)

Biotech Stock Roundup: CoLucid Soars on Migraine Data, Dynavax Drug FDA Panel Meeting Cancelled
Arpita Dutt - Zacks Investment Research - Wed Sep 07, 8:30AM CDT
Although it was a relatively slow week for the biotech sector, companies like CoLucid (CLCD) and Dynavax were in the news with pipeline updates.
DVAX: 11.62 (-0.05), BIIB: 314.81 (+2.81), CLCD: 31.06 (-2.15), BMRN: 97.45 (-0.12), ALXN: 133.69 (+3.33), AMGN: 175.62 (+1.77), SPPI: 4.81 (+0.34)

Research Reports Coverage on Biotech Stocks -- Biogen, ImmunoGen, Jazz Pharma, and Cempra
PR Newswire - Wed Sep 07, 7:05AM CDT
The Biotech arena took a beating at the start of this year, but recent major takeovers have started drawing investors' interests back toward the industry. Stock-Callers.com shifts investors' attention to these four equities and see if they are positioned for long-term growth: Biogen Inc. (NASDAQ: BIIB), ImmunoGen Inc. (NASDAQ: IMGN), Jazz Pharmaceuticals PLC (NASDAQ: JAZZ), and Cempra Inc. (NASDAQ: CEMP). These stocks research reports can be downloaded now by simply registering for free at:
BIIB: 314.81 (+2.81), JAZZ: 126.65 (-2.16), IMGN: 2.87 (-0.01), CEMP: 24.60 (-0.01)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Modeling and Mental Health Join Forces for Wellness

A Fresh Alliance for Mental Wellness in Modeling Alright, let's shine a spotlight on a significant step in the modeling industry, a place typically less vocal about mental health. In a move that feels long overdue, Brain-Body Therapy and Mother Model Management have joined forces, marking the beginning of a collaborative effort to propel mental wellness to the forefront...

QuickFi Nabs Top Finovate Award for Fourth Time

An Unstoppable Force in Fintech Well, if QuickFi hasn't made a name for itself in fintech, then folks, I don't know what to tell you. This year, they’ve snagged yet another prestigious Finovate Award—this time for Best SMB/SME Banking Solution. That's not their first rodeo either; it’s the fourth time they’ve walked away winners. It's almost like they're...

Intus Bio Secures $2.7M for Colorectal Cancer Test

Pioneering Efforts in Early-Onset Colorectal Cancer Detection The battlefield of colorectal cancer prevention just got a serious upgrade with Intus Bio grabbing a $2.7 million award. This ain't just pocket change—it's a shot at rewriting the script on how we approach early-onset colorectal cancer, the pesky number one cancer gnawing at the under-50 crowd. Partnering...

Streamlined AI Video Analytics for Public Safety Unveiled

AI Without the Headache Alright folks, IREX is shaking things up, and not in the usual iterative, bit-by-bit tech progression way. StreamVLM™ has been rolled out as the world's first vision-language model (VLM) analytics engine tailored for the public safety sector—specifically, for cloud platforms. I’ve been around the block enough times to spot a significant shift...

Jari Spirits Set to Shake Up U.S. Market After Big Wins

Korean Spirits Jari Eyes U.S. Market Entry Some stories just have that perfect 'right time, right place' vibe, and CJ Foods' recent splash with their Korean spirits brand jari is one of them. Buckle up, because this one's about a Korean distilling sensation gearing up to hit American shores with a bang. Accolades Pave the Path Jari, the premium Korean distilled spirits...

Lick the Plate Hits 2,000 Shows with Clown Band

They say good things come in bizarre packages, and that's exactly the case as David Boylan's Lick the Plate zany celebration marks 15 years on air with its 2,000th episode. If you think of radio as a predictable endeavor, well, you're not tuned into Lick the Plate. A Milepost Draped in Multicolored Fabrics When you're browsing through colorful avenues of radio fame, it's...

Sustainability Investments: $17 Trillion Wager Faces Divergence

Sustainability Investments: A Tale of Contrasts In the world of sustainability, a staggering $17 trillion has been poured into technologies over the past decade. That’s no chump change. But what do we have to show for it? According to Bain & Company’s latest report, this massive financial injection hasn’t exactly hit a home run. Progress, much like the stock market...

Americas Cardroom's Poker Series Hits $7.2M Haul

Massive Prize Pools Emerge in Just Four Days I found myself eyeballing some jaw-dropping numbers from Americas Cardroom's latest poker series, the Online Super Series XL. It's not every day you see nearly a hundred tournaments rake in over $7.2 million in prize pools in just four days. From September 6th to 9th, a whopping 62,847 entries signed up to make an honest...

Fermi's Founder Pushes for Board Overhaul: What's Next?

Fermi's Roller Coaster: A Founder’s Stand Seems like Fermi Inc. is on a wild ride through the business landscape, and it's giving shareholders more whiplash than satisfaction these days. Toby Neugebauer, co-founder of Fermi and the loudest voice in the room, is feeling like his company is facing some serious turbulence and seems determined not to sit idly by as it hits...

High-Grade Copper Spurs Optimism for PolarX in Alaska

Copper's New Pulse: PolarX Makes Waves in Alaska Ever hear about striking copper so rich it's practically shimmering? Well, PolarX Limited just might have hit that sweet spot up in the rugged expanses of Alaska. Let me tell you, when you're knee-deep in resources, like what they’re discovering at the Caribou Dome Project, it sure feels like you’ve struck modern-day...